Prasugrel
Ugramel, which contains the active substance prasugrel, belongs to a group of medicines called antiplatelet medicines. Platelets are very small blood cells that circulate in the blood. When a blood vessel is damaged, for example, cut, platelets clump together to help form a blood clot. Platelets play a crucial role in stopping bleeding. The formation of a blood clot in a hardened, atherosclerotic blood vessel, such as an artery, is very dangerous, as it can lead to a blockage of blood flow, causing a heart attack (myocardial infarction), stroke, or death. The presence of a blood clot in the arteries that supply blood to the heart can limit blood flow and cause unstable angina (severe chest pain). Ugramel prevents platelets from clumping together, thereby reducing the risk of blood clots. Ugramel has been prescribed by your doctor because you have had a heart attack or unstable angina, and you have previously undergone a procedure to unblock clogged arteries in your heart. You may have had a procedure where one or more stents were placed to keep a blocked or narrowed artery that supplies blood to your heart open. Ugramel reduces the risk of another heart attack, stroke, or death due to one of these events. Your doctor will also recommend taking acetylsalicylic acid (e.g., aspirin), which is also an antiplatelet medicine.
If any of the following situations apply to you, you should inform your doctor before taking Ugramel:
You should immediatelyinform your doctor if you experience a medical condition called thrombotic thrombocytopenic purpura (TTP), which is characterized by: fever and bruising under the skin, which may look like red pinpoint spots, with or without symptoms of extreme fatigue, confusion, yellowing of the skin or eyes (jaundice) (see section 4 "Possible side effects").
Ugramel should not be used in children and adolescents under 18 years of age.
You should tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take. In particular, you should inform your doctor if you are taking clopidogrel (an antiplatelet medicine), warfarin (an anticoagulant medicine), or "non-steroidal anti-inflammatory drugs" used to treat pain and fever (such as ibuprofen, naproxen, etoricoxib). Taking these medicines with Ugramel may increase the risk of bleeding. You should inform your doctor if you are taking morphine or other opioids (used to treat severe pain). While taking Ugramel, you should only take other medicines if your doctor allows it.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before taking this medicine. Ugramel should only be used after discussing the potential benefits and risks to the unborn child with your doctor.
It is unlikely that Ugramel will affect your ability to drive or use machines.
If you have been diagnosed with an intolerance to some sugars, you should contact your doctor before taking this medicine.
This medicine should always be taken exactly as your doctor has instructed. If you are unsure, you should ask your doctor or pharmacist. The usual dose of Ugramel is 10 mg once daily. You should start treatment with a single dose of 60 mg. If you weigh less than 60 kg or are over 75 years old, the daily dose is 5 mg. Ugramel is not available in a 5 mg dose. Your doctor will recommend a dose of acetylsalicylic acid (usually between 75 mg and 325 mg once daily). You can take Ugramel with or without food. You should take your dose at the same time every day. Do not break or crush the tablets. It is very important to inform your doctor, dentist, and pharmacist that you are taking Ugramel.
You should immediatelycontact your doctor or hospital due to the increased risk of bleeding. You should show your doctor the Ugramel packaging.
If you miss a dose, you should take it as soon as possible. If you forget to take a dose for the entire day, you should take the next dose of Ugramel at the usual time the next day. Do not take a double dose to make up for the missed dose.
Do not stop taking Ugramel without consulting your doctor. Stopping Ugramel too quickly may increase the risk of a heart attack. If you have any doubts about taking this medicine, you should ask your doctor or pharmacist.
Like all medicines, Ugramel can cause side effects, although not everybody gets them. You should immediatelycontact your doctor if you experience:
You should also immediatelycontact your doctor if you experience:
All of the above symptoms may indicate bleeding, the most common side effect of Ugramel. Severe bleeding, although uncommon, can be life-threatening. Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1000 people):
If you experience any side effects, including those not listed in this leaflet, you should inform your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw. Tel.: 22 49 21 301, fax: 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder or its representative in Poland. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children. Do not use this medicine after the expiry date stated on the blister and packaging (EXP). The expiry date refers to the last day of the month. Store in a temperature below 25°C. Store in the original packaging to protect from moisture and light. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
White or almost white, elongated, film-coated tablet, 10.6 mm x 5.4 mm in size. Available pack sizes: 28, 30, or 98 tablets. Not all pack sizes may be marketed.
Zentiva k.s., U kabelovny 130, Dolní Mĕcholupy, 102 37 Prague 10, Czech Republic
Zentiva k.s., U kabelovny 130, Dolní Mĕcholupy, 102 37 Prague 10, Czech Republic, S.C. Zentiva S.A., 50 Theodor Pallady Blvd., District 3, 032266, Bucharest, Romania
Zentiva Polska Sp. z o.o., ul. Bonifraterska 17, 00-203 Warsaw, Tel. (22) 375 92 00, Date of revision of the leaflet:November 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.